Search

Search Constraints

You searched for: Author/Creator Albala, Bruce

Search Results

2. [P1–043]: ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG. (1st July 2017)

3. [P2–003]: ELENBECESTAT PHARMACOKINETIC DRUG‐DRUG INTERACTIONS INDICATED NO DOSAGE ADJUSTMENTS REQUIRED FOR MOST CONCOMITANT TREATMENTS. (1st July 2017)

5. Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Issue 4 (1st October 2016)

6. IC‐P‐040: EVALUATION OF TAU DEPOSITION IN AMYLOID POSITIVE MCI OR MILD‐AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

7. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Issue 1 (9th October 2022)

8. O4‐12‐05: EVALUATION OF TAU DEPOSITION IN AMYLOID‐POSITIVE MCI OR MILD AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

9. P1‐040: ELENBECESTAT, A NOVEL BACE INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS AND TOLERABILITY IN JAPANESE SUBJECTS WITH MULTIPLE DOSINGS. (1st July 2006)